1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents growing 6.22% while Biotechnology shows decline of -6.94%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
-100.00%
Short-term investments yoy growth below half the Biotechnology median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
6.22%
Below half the Biotechnology median of -2.11% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
13.80%
Below half the Biotechnology median of -3.70%. Jim Chanos would question if the company faces working capital strain.
2.11%
PP&E growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Below half the Biotechnology median of -1.63%. Jim Chanos might see potential stagnation or distress vs. peers.
62.36%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-40.14%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
133.46%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
184.58%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
173.41%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
4.06%
Above 1.5x Biotechnology median of 0.02%. Jim Chanos suspects heavier share issuance than peers.
-25.11%
≥ 1.5x Biotechnology median of -2.90%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-90.06%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-763.59%
≥ 1.5x Biotechnology median of -0.78%. Joel Greenblatt sees stronger equity growth vs. peers.
13.78%
Below half Biotechnology median of -2.23%. Jim Chanos suspects a major slowdown or distress.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-40.14%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-7.59%
Below half of Biotechnology median 6.07%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
